Duke University

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.



Approved or authorized vaccines
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
The U.S.…

Two U.S. FDA priority review voucher (PRV) transactions took place on Monday: Belgian immunology specialist Argenx paid $98 million to Bayer for the pharma giant’s voucher and California-based Eiger BioPharmaceuticals sold its voucher to an undisclosed buyer for $95 million.

PRVs are now routinely selling for less than one-third of their 2015 high of $350 million, according to data monitored by Duke University’s David Ridley, a creator of the PRV program.